Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

Uno studio per confrontare le caratteristiche farmacocinetiche, la sicurezza, la tollerabilità e l'immunogenicità di HLX15-SC con DARZALEX FASPRO® in combinazione con lenalidomide e desametasone (Rd) in pazienti non idonei al trapianto con mieloma multiplo di nuova diagnosi

21 settembre 2026 aggiornato da: Shanghai Henlius Biotech

Uno studio randomizzato, in doppio cieco, controllato in parallelo di Fase I per confrontare le caratteristiche farmacocinetiche, la sicurezza, la tollerabilità e l'immunogenicità di HLX15-SC con DARZALEX FASPRO® in combinazione con lenalidomide e desametasone (Rd) in pazienti non idonei al trapianto con mieloma multiplo di nuova diagnosi

The purpose of this study is to compare the pharmacokinetic (PK) similarity, safety, tolerability, immunogenicity, and efficacy of HLX15-SC versus US-DARZALEX FASPRO® following single and multiple subcutaneous (SC) injections in newly diagnosed MM patients ineligible for transplant.

Participants who meet all inclusion criteria and none of the exclusion criteria will receive either the HLX15-SC-Rd regimen or the D-Rd regimen for 4 cycles (one cycle = 4 weeks). After 4 cycles of treatment, based on clinical benefit and participant preference, participants may continue to receive the locally marketed daratumumab subcutaneous formulation (Dara-SC) in combination with Rd according to clinical practice, up to 32 weeks or until loss of clinical benefit, death, unacceptable toxicity, withdrawal of informed consent, or any other protocol-specified reason, whichever occurs first. After 32 weeks of dosing, participants will continue to receive appropriate standard of care according to local guidelines (including marketed Dara-SC).

Panoramica dello studio

Stato

Reclutamento

Condizioni

Intervento / Trattamento

Tipo di studio

Interventistico

Iscrizione (Stimato)

258

Fase

  • Fase 1

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Contatto studio

Luoghi di studio

  • Australia
      • Perth, Australia, 6005
        • Reclutamento
        • Perth Blood Institute
  • Cina
    • Anhui
      • Bengbu, Anhui, Cina, 233000
        • Reclutamento
        • The First Affiliated Hospital of Bengbu Medical University
      • Hefei, Anhui, Cina, 230601
        • Reclutamento
        • The Second Affiliated Hospital of Anhui Medical University
      • Hefei, Anhui, Cina, 230031
        • Reclutamento
        • Anhui Provincial Cancer Hospital
    • Beijing Municipality
      • Beijing, Beijing Municipality, Cina, 100191
        • Reclutamento
        • Peking University Third Hospital
      • Beijing, Beijing Municipality, Cina, 100035
        • Reclutamento
        • Peking University First Hospital
      • Beijing, Beijing Municipality, Cina, 100027
        • Reclutamento
        • Beijing Chao-Yang Hospital Capital Medical University
    • Chongqing Municipality
      • Chongqing, Chongqing Municipality, Cina, 400016
        • Reclutamento
        • The First Affiliated Hospital of Chongqing Medical University
    • Fujian
      • Fuzhou, Fujian, Cina, 350004
        • Reclutamento
        • The First Affiliated Hospital of Fujian Medical University
      • Xiamen, Fujian, Cina, 361001
        • Reclutamento
        • The First Affiliated Hospital of Xiamen University
    • Guangdong
      • Guangzhou, Guangdong, Cina, 510080
        • Reclutamento
        • Guangdong General Hospital
      • Guangzhou, Guangdong, Cina, 510013
        • Reclutamento
        • Guangzhou First People's Hospital
      • Guangzhou, Guangdong, Cina, 510220
        • Reclutamento
        • Zhujiang Hospital of Southern Medical University
      • Meizhou, Guangdong, Cina, 514031
        • Reclutamento
        • Meizhou People's Hospital
      • Shenzhen, Guangdong, Cina, 518020
        • Reclutamento
        • Shenzhen People's Hospital
      • Shenzhen, Guangdong, Cina, 518036
        • Reclutamento
        • Peking University Shenzhen Hospital
    • Guangxi
      • Liuzhou, Guangxi, Cina, 545007
        • Reclutamento
        • Liuzhou Worker's Hospital
      • Nanning, Guangxi, Cina, 530213
        • Reclutamento
        • Guangxi Medical University Cancer Hospital
    • Guizhou
      • Guiyang, Guizhou, Cina, 550004
        • Reclutamento
        • The Affiliated Hospital of Guizhou Medical University
    • Hebei
      • Baoding, Hebei, Cina, 071030
        • Reclutamento
        • Affiliated Hospital of Hebei University
      • Cangzhou, Hebei, Cina, 061000
        • Reclutamento
        • Cangzhou People's Hospital
      • Shijiazhuang, Hebei, Cina, 050071
        • Reclutamento
        • The Second Hospital of Hebei Medical Universit
      • Shijiazhuang, Hebei, Cina, 050052
        • Reclutamento
        • Hebei medical university third hospital
    • Heilongjiang
      • Harbin, Heilongjiang, Cina, 150069
        • Reclutamento
        • Harbin Medical University Cancer Hospital
    • Henan
      • Luoyang, Henan, Cina, 471003
        • Reclutamento
        • The First Affiliated Hospital of Henan University of Science & Techinology
      • Xinxiang, Henan, Cina, 453000
        • Reclutamento
        • Xinxiang Central Hospital
      • Zhengzhou, Henan, Cina, 450003
        • Reclutamento
        • Henan Cancer Hospital
      • Zhengzhou, Henan, Cina, 450052
        • Reclutamento
        • The First Affiliated Hospital of Zhengzhou University
      • Zhengzhou, Henan, Cina, 450003
        • Reclutamento
        • Henan Provincial People's Hospital
    • Hubei
      • Wuhan, Hubei, Cina, 430071
        • Reclutamento
        • Zhongnan Hospital of Wuhan University
      • Wuhan, Hubei, Cina, 430061
        • Reclutamento
        • Renmin Hospital of Wuhan University
      • Wuhan, Hubei, Cina, 430014
        • Reclutamento
        • Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
      • Wuhan, Hubei, Cina, 430030
        • Reclutamento
        • Tongji Hospital Affiliated to Tongji Medical College of Huazhong University of Science & Technology
    • Hunan
      • Changsha, Hunan, Cina, 410011
        • Reclutamento
        • The Second Xiangya Hospital of Central South University
      • Hengyang, Hunan, Cina, 421001
        • Reclutamento
        • The First Affiliated Hospital Of University South China
    • Inner Mongolia
      • Hohhot, Inner Mongolia, Cina, 010030
        • Reclutamento
        • The Affiliated Hospital of Inner Mongolia Medical University
    • Jangxi
      • Nanchang, Jangxi, Cina, 330008
        • Reclutamento
        • The First Affiliated Hospital of Nanchang University
      • Nanchang, Jangxi, Cina, 330008
        • Reclutamento
        • The second affiliated hospital of Nanchang University
    • Jiangsu
      • Nanjing, Jiangsu, Cina, 210009
        • Reclutamento
        • Zhongda Hospital Southeast University
      • Nanjing, Jiangsu, Cina, 211166
        • Reclutamento
        • Sir Run Run Hospital of Nanjing Medical University
      • Suzhou, Jiangsu, Cina, 215004
        • Reclutamento
        • Nuclear Industry General Hospital (The Second Affiliated Hospital of Soochow University)
      • Wuxi, Jiangsu, Cina, 214000
        • Reclutamento
        • Affiliated Hospital of Jiangnan University
      • Xuzhou, Jiangsu, Cina, 221006
        • Reclutamento
        • The Affiliated Hospital of Xuzhou Medical University
    • Jiangxi
      • Ganzhou, Jiangxi, Cina, 341000
        • Reclutamento
        • First Affiliated Hospital of Gannan Medical University
      • Nanchang, Jiangxi, Cina, 330029
        • Reclutamento
        • Jiangxi Cancer Hospital
    • Liaoning
      • Dalian, Liaoning, Cina, 116001
        • Reclutamento
        • Affiliated Zhongshan Hospital of Dalian University
      • Shenyang, Liaoning, Cina, 110004
        • Reclutamento
        • Shengjing Hospital of China Medical University
      • Shenyang, Liaoning, Cina, 110001
        • Reclutamento
        • The First Hospital of China Medical University
      • Shenyang, Liaoning, Cina, 110041
        • Reclutamento
        • Liaoning Cancer Hospital & Institute
    • Shandong
      • Jinan, Shandong, Cina, 250022
        • Reclutamento
        • Shandong Provincial Hospital
      • Jining, Shandong, Cina, 272000
        • Reclutamento
        • Jining No.1 People's Hospital
      • Qingdao, Shandong, Cina, 266001
        • Reclutamento
        • The Affiliated Hospital of Qingdao University
      • Weifang, Shandong, Cina, 261041
        • Reclutamento
        • Weifang People's Hospital
    • Shanghai Municipality
      • Shanghai, Shanghai Municipality, Cina, 200032
        • Reclutamento
        • Zhongshan Hospital, Fudan University
    • Shanxi
      • Taiyuan, Shanxi, Cina, 030001
        • Reclutamento
        • The Second Hospital of Shanxi Medical University
      • Taiyuan, Shanxi, Cina, 030013
        • Reclutamento
        • Shanxi Cancer Hospital
    • Sichuan
      • Chengdu, Sichuan, Cina, 610041
        • Reclutamento
        • Sichuan Cancer Hospital
      • Chengdu, Sichuan, Cina, 610073
        • Reclutamento
        • Sichuan Academy of Medical Sciences & Sichuan Provincial People's Hospital
    • Tianjin Municipality
      • Tianjin, Tianjin Municipality, Cina, 300060
        • Reclutamento
        • Tianjin Medical University Cancer Institute & Hospital
      • Tianjin, Tianjin Municipality, Cina, 300308
        • Reclutamento
        • Tianjin Cancer Hospital Airport Hospital
      • Tianjin, Tianjin Municipality, Cina, 300131
        • Reclutamento
        • Tianjin People's Hospital
    • Zhejiang
      • Hangzhou, Zhejiang, Cina, 310006
        • Reclutamento
        • Hangzhou First People's Hospital
      • Hangzhou, Zhejiang, Cina, 310015
        • Reclutamento
        • Zhejiang Provincial People's Hospital
      • Hangzhou, Zhejiang, Cina, 310016
        • Reclutamento
        • Sir Run Run Shaw Hospital Zhejiang University School of Medicine（The Grand Canal Campus）
      • Hangzhou, Zhejiang, Cina, 310020
        • Reclutamento
        • The First Affiliated Hospital, Zhejiang University School of Medicine
      • Ningbo, Zhejiang, Cina, 315010
        • Reclutamento
        • The First Affiliated Hospital of Ningbo University
      • Wenzhou, Zhejiang, Cina, 325000
        • Reclutamento
        • The Second Affiliated Hospital of Wenzhou Medical University
  • Georgia
      • Tbilisi, Georgia, 0159
        • Non ancora reclutamento
        • JSC K. Eristavi National Center of Experimental and Clinical Surgery
      • Tbilisi, Georgia, 0160
        • Non ancora reclutamento
        • LLC Caucasus Medical Centre
  • Serbia
      • Belgrade, Serbia, 11080
        • Non ancora reclutamento
        • Clinical Hospital Centre Zemun
      • Kragujevac, Serbia, 34000
        • Non ancora reclutamento
        • University Clinical Center Kragujevac
      • Niš, Serbia, 8000
        • Non ancora reclutamento
        • University Clinical Center Nis
  • Stati Uniti
    • Arkansas
      • Springdale, Arkansas, Stati Uniti, 72762
        • Reclutamento
        • Highlands Oncology Group, PA
    • Florida
      • Jacksonville, Florida, Stati Uniti, 32256
        • Reclutamento
        • Cancer Specialists of North Florida
      • Margate, Florida, Stati Uniti, 33063
        • Reclutamento
        • D&H National Research Center
      • Ocala, Florida, Stati Uniti, 34474
        • Reclutamento
        • Ocala Oncology Center
      • Plantation, Florida, Stati Uniti, 33322
        • Reclutamento
        • Florida Clinical Trials Group
      • Tamarac, Florida, Stati Uniti, 33321
        • Reclutamento
        • Florida Clinical Trials Group
    • Indiana
      • Dyer, Indiana, Stati Uniti, 46311
        • Reclutamento
        • Genesis Medical Research
    • Louisiana
      • Covington, Louisiana, Stati Uniti, 70433
        • Reclutamento
        • Pontchartrain Cancer Center
    • Texas
      • Houston, Texas, Stati Uniti, 77030
        • Reclutamento
        • Oncology Consultants (P1 Trials -Exigent Network)
      • Houston, Texas, Stati Uniti, 77090
        • Reclutamento
        • Lumi Research
    • Washington
      • Everett, Washington, Stati Uniti, 98201
        • Reclutamento
        • Optum Care Washington
      • Olympia, Washington, Stati Uniti, 98506
        • Reclutamento
        • American Oncology Network Vista Oncology Division / Physician partner associate

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

18 anni e precedenti (Adulto, Adulto più anziano)

Accetta volontari sani

No

Sessi ammissibili allo studio

Tutto

Descrizione

Inclusion Criteria:

  1. Age ≥ 18 years at the time of signing the informed consent form (ICF).

  2. Body mass index (BMI): 18.5 kg/m2 ≤ BMI < 28 kg/m2.

  3. Subjects must participate voluntarily, understand the study, and sign the ICF.

  4. Patients must have a documented diagnosis of multiple myeloma (MM) according to the International Myeloma Working Group (IMWG) criteria, with measurable lesion .

  5. Serum albumin ≥ 35 g/L.

  6. Newly diagnosed, untreated, and considered ineligible for high-dose chemotherapy with autologous stem cell transplantation (ASCT) by the investigator.

  7. The patient's ECOG performance status must be 0 or 1 .

  8. Patient must have clinical laboratory values meeting the following criteria during the screening period:

    1. Hemoglobin ≥ 7.5 g/dL (≥ 5 mmol/L; red blood cell [RBC] transfusion or use of recombinant human erythropoietin at least 1 week prior to randomization is allowed).
    2. Absolute neutrophil count (ANC) ≥ 1.0 × 109/L (use of granulocyte-colony stimulating factor [G-CSF] is allowed).
    3. Alanine aminotransferase (ALT) ≤ 2.5 × upper limit of normal (ULN).
    4. Without the following evidence of impaired liver function, including mild impairment (total bilirubin ≤ ULN and AST > ULN or ULN < total bilirubin ≤ 1.5 x ULN), moderate impairment (1.5 x ULN < total bilirubin ≤ 3 x ULN), and severe impairment (total bilirubin > 3 x ULN).
    5. Measured creatinine clearance ≥ 40 mL/min .
    6. Corrected serum calcium < 14 mg/dL (< 3.5 mmol/L); or free ionized calcium < 6.5 mg/dL (< 1.6 mmol/L) .
    7. Platelet count ≥ 70 × 109/L for patients with plasma cells < 50% of bone marrow nucleated cells; platelet count > 50 × 109/L for all other patients (transfusion within 3 days prior to randomization to achieve the minimum platelet count is not permitted).

  9. Contraceptive criteria: Contraceptive use by men or women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.

    1. Female patients: a female patient is eligible to participate if she is not pregnant or breastfeeding, and at least one of the following conditions applies:

      Not a woman of childbearing potential (WOCBP) or WOCBP: must commit to either abstain continuously from heterosexual sexual intercourse or to use 2 methods of reliable birth control simultaneously from signed ICF to at least 140 days following the last dose of study products. This includes one highly effective contraceptive method with a failure rate of < 1% per year (tubal ligation, intrauterine device, hormonal [birth control pills, injections, hormonal patches, vaginal rings or implants] or partner's vasectomy) and one additional effective contraceptive method (male latex or synthetic condom, diaphragm, or cervical cap). Reliable contraception is indicated even where there has been a history of infertility, unless due to hysterectomy or bilateral oophorectomy.

      The subjects also need to agree not to donate or cryopreservation eggs (ova, oocytes) from signed ICF to at least 140 days following the last dose of study products.

    2. Male patients: male patients are eligible to participate if they agree to the following during the intervention period and for at least 140 days following the last dose of study products:

    Be abstinent from heterosexual intercourse as their preferred and usual lifestyle (abstinent on a long-term and persistent basis) and agree to remain abstinent.

    or Agree to use a male condom and female partner to use an additional highly effective contraceptive method with a failure rate of <1% per year as when having sexual intercourse with a woman of childbearing potential who is not currently pregnant.

    Agree not to donate or cryopreservation sperm.

  10. A WOCBP must have a negative serum pregnancy test at screening within 72 h prior to randomization. The investigator is responsible for review of medical history, menstrual history, and recent sexual activity to decrease the risk for inclusion of a woman with an early undetected pregnancy

Exclusion Criteria:

  1. Patient has a diagnosis of primary amyloidosis, monoclonal gammopathy of undetermined significance (MGUS), smoldering multiple myeloma (SMM), Waldenström's disease, or other conditions in which IgM M-protein is present in the absence of a clonal plasma cell infiltration with lytic bone lesions.

  2. Patient has plasma cell leukemia (according to IMWG criterion: ≥ 5% of plasma cells in the peripheral blood and/or an absolute plasma cell count of ≥ 2 x 109/L) or POEMS syndrome (polyneuropathy, organomegaly, endocrinopathy, monoclonal protein, and skin changes).

  3. Patient has prior or current systemic therapy or ASCT for MM, with the exception of an emergency use of a short course (equivalent of dexamethasone 40 mg/day for a maximum 4 days) of corticosteroids before randomization.

  4. Patient has peripheral neuropathy or neuropathic pain Grade 2 or higher, as defined by the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) Version 6.

  5. Patient has a history of malignancy (other than MM) within 3 years before the date of randomization (exceptions are squamous and basal cell carcinomas of the skin and carcinoma in situ of the cervix, or malignancy that in the opinion of the investigator is considered cured with minimal risk of recurrence within 3 years).

  6. Patient has clinical signs of meningeal involvement of MM.

  7. Patient has known chronic obstructive pulmonary disease (COPD) (defined as a forced expiratory volume in 1 second [FEV1] < 50% of predicted normal), persistent asthma, or a history of asthma within the last 2 years. Patient with known or suspected COPD or asthma must have a FEV1 test during screening.

  8. Patient is known to be seropositive for history of human immunodeficiency virus (HIV) or known to have treponema pallidum antibodies (Anti-TP).

  9. Patient is known to have active hepatitis B or C.

    1. Patient is seropositive for hepatitis B (defined by a positive test for hepatitis B surface antigen [HBsAg]). Patients with resolved infection (that is, patients who are HBsAg negative but positive for antibodies to hepatitis B core antigen [Anti-HBc] and/or antibodies to hepatitis B surface antigen [Anti-HBs]) must be screened using real-time polymerase chain reaction (PCR) measurement of hepatitis B virus (HBV) deoxyribonucleic acid (DNA) levels. Those who are PCR positive will be excluded.

      EXCEPTION: Patients with serologic findings suggestive of HBV vaccination (Anti-HBs positivity as the only serologic marker) AND a known history of prior HBV vaccination, do not need to be tested for HBV DNA by PCR.

    2. Patient is seropositive for hepatitis C must be screened using PCR measurement of hepatitis C virus (HCV) ribonucleic acid (RNA) levels. Those who are PCR positive will be excluded.

  10. Patient has any concurrent medical or psychiatric condition or disease (e.g., active systemic infection, uncontrolled diabetes, acute diffuse infiltrative pulmonary disease) that is likely to interfere with the study procedures or results, or that in the opinion of the investigator, would constitute a hazard for participating in this study.

  11. Patient has clinically significant cardiac disease, including:

    1. Myocardial infarction within 1 year before randomization, or an unstable or uncontrolled disease/condition related to or affecting cardiac function (e.g., unstable angina, congestive heart failure, New York Heart Association [NYHA] Class III-IV ).
    2. Cardiac arrhythmia (NCI-CTCAE Version 6 Grade ≥ 2) or clinically significant ECG abnormalities.
    3. Screening 12-lead ECG showing a baseline QT interval as corrected by Fridericia's formula (QTcF) (See Appendix 6) > 470 ms.

  12. Patient has known allergies, hypersensitivity, or intolerance to lenalidomide, corticosteroids, monoclonal antibodies or human proteins, or their excipients or known sensitivity to mammalian-derived products.

  13. Patient has history of drug abuse or substance abuse one year prior to randomization. Patient is known or suspected of not being able to comply with the study protocol (e.g., because of alcoholism, drug dependency, or psychological disorder).

  14. Patient is a woman who is pregnant, or breast-feeding, or planning to become pregnant or donate eggs (ova, oocytes) while enrolled in this study or within 140 days after the last dose of study products.

    Or patient is a man who plans to father a child and/or donate sperm while enrolled in this study or within 140 days after the last dose of study products.

    Patient does not agree to abstain completely from sexual intercourse, or plan to use a contraceptive method that is not acceptable to the investigator (unacceptable methods of contraception include: i. periodic abstinence [such as calendar method, ovulation method, basal body temperature method, post-ovulation safety period method, etc.], withdrawal, etc.; ii. medical contraceptive measures such as oral contraceptives, contraceptive injections, contraceptive patches, subcutaneous implantation, intrauterine hormone contraceptive devices, local contraceptives such as spermicides, etc.).

  15. Patient had radiation therapy within 14 days of randomization.

  16. Patient had plasmapheresis within 28 days of randomization.

  17. Patient had a history of blood donation or total blood loss of 200 mL or more within 3 months before randomization.

  18. Patient had major surgery within 28 days before randomization or has not fully recovered from surgery, or has surgery planned during the time the patient is expected to participate in the study or within 28 days after the last dose of study treatment. Kyphoplasty is not considered major surgery.

  19. Patient in clinical trials of any other drug or device within 3 months (or 5 half-lives of the corresponding investigational product if the half-life of the drug is long [5 half-lives > 3 months]) before randomization.

  20. Patient has any condition for which, in the opinion of the investigator, participation would not be in the best interest of the patient (e.g., compromise the well-being) or that could prevent, limit, or confound the protocol-specified assessments

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Scopo principale: Trattamento
  • Assegnazione: Randomizzato
  • Modello interventistico: Assegnazione parallela
  • Mascheramento: Quadruplicare

Armi e interventi

Gruppo di partecipanti / Arm
Intervento / Trattamento
Sperimentale: HLX15-SC-Rd

HLX15-SC-Rd
Droga: HLX15-SC-Rd

Subjects will receive 1800 mg HLX15-SC via SC administration for up to 16 weeks: weekly during Week 1-8 (Cycle 1-2; 1 cycle = 4 weeks) and every two weeks during Week 9-16 (Cycle 3-4).
Comparatore attivo: US-DARZALEX FASPRO®-Rd

US-DARZALEX FASPRO®-Rd
Droga: US-DARZALEX FASPRO®-Rd

Subjects will receive 1800 mg US-DARZALEX FASPRO® via SC administration for up to 16 weeks: weekly during Week 1-8 (Cycle 1-2; 1 cycle = 4 weeks) and every two weeks during Week 9-16 (Cycle 3-4).

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
pharmacokinetic (PK) similarity
Lasso di tempo: 7 days

Area under the serum concentration-time curve from time 0 to day 7 (AUC0-7d) after the 1st dose.
7 days
pharmacokinetic (PK) similarity
Lasso di tempo: 7 days

The maximum (peak) serum drug concentration (Cmax) after the 1st dose.
7 days
pharmacokinetic (PK) similarity
Lasso di tempo: 16 weeks

Area under the serum concentration-time curve within a dosing interval at steady-state (AUCss) after the 12th dose
16 weeks
pharmacokinetic (PK) similarity
Lasso di tempo: 16 weeks

The maximum (peak) serum drug concentration at steady-state (Cmax,ss) after the 12th dose
16 weeks

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
PK characteristics
Lasso di tempo: 16 weeks

trough concentration (Ctrough)
16 weeks
PK characteristics
Lasso di tempo: 16 weeks

trough concentration at steady state (Ctrough,ss).
16 weeks
Safety: Adverse events (AEs), serious adverse events (SAEs), and adverse events of special interest (AESIs)
Lasso di tempo: 16 weeks

Adverse events (AEs), serious adverse events (SAEs), and adverse events of special interest (AESIs) terms and frequency of occurrence judged by investigators
16 weeks
Safety: Vital Signs
Lasso di tempo: 16 weeks

Vital Signs: including blood pressure (systolic and diastolic; mmHg) , pulse rate (beats/min) measured by hematomanometer
16 weeks
Safety: Vital Signs
Lasso di tempo: 16 weeks

including body temperature (°C) measured by clinical thermometer
16 weeks
Safety: Physical examinations
Lasso di tempo: 16 weeks

Physical examinations: includes general condition; head and neck; mucous membranes; chest; abdomen; spine; extremities; musculoskeletal system; neurological system; lymphatic system; and skin checked by investigators
16 weeks
Safety: Laboratory tests
Lasso di tempo: 16 weeks

Laboratory tests: include hematology, blood chemistry, and urinalysis measured by the department of medical laboratory in site
16 weeks
Safety: Electrocardiography
Lasso di tempo: 16 weeks

Electrocardiography: 12-lead ECG will be performed by qualified personnel using an ECG machine, includes heart rate（beats per minute ）
16 weeks
Safety: Electrocardiography
Lasso di tempo: 16 weeks

Electrocardiography: 12-lead ECG will be performed by qualified personnel using an ECG machine, includes PR interval（msec）.
16 weeks
Safety: Electrocardiography
Lasso di tempo: 16 weeks

Electrocardiography: 12-lead ECG will be performed by qualified personnel using an ECG machine, includes QRS duration (msec).
16 weeks
Safety: Electrocardiography
Lasso di tempo: 16 weeks

Electrocardiography: 12-lead ECG will be performed by qualified personnel using an ECG machine, includes QTc interval (msec).
16 weeks
Immunogenicity:
Lasso di tempo: 16 weeks

Incidence of anti-drug antibodies (ADA) and neutralizing antibodies (NAb) against the study products (HLX15-SC and US-DARZALEX FASPRO®) and hyaluronidase.
16 weeks
Efficacy:ORR
Lasso di tempo: 16 weeks

Investigator-assessed overall response rate (ORR): is defined as the percentage of all patients achieving a PR or better after the randomization date.
16 weeks
Efficacy: partial response (PR) rate
Lasso di tempo: 16 weeks

Partial response (PR) rate is defined as the percentage of all patients achieving a PR at any time point after the randomization date
16 weeks
Efficacy: very good partial response (VGPR) rate
Lasso di tempo: 16 weeks

Very good partial response (VGPR) rate is defined as the percentage of all patients achieving a VGPR at any time point after the randomization date.
16 weeks
Efficacy: complete response (CR) rate
Lasso di tempo: 16 weeks

Complete response (CR) rate is defined as the percentage of all patients achieving a CR at any time point after the randomization date.
16 weeks
Efficacy: stringent complete response (sCR) rate
Lasso di tempo: 16 weeks

Stringent complete response (sCR) rate is defined as the percentage of all patients achieving an sCR at any time point after the randomization date.
16 weeks
Efficacy: time to response
Lasso di tempo: 16 weeks

Time to Response (TTR) is defined as the time from randomization to the first documented response of PR or better. TTR will be analyzed only for patients who achieve a response of PR or better.
16 weeks

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Sponsor

Shanghai Henlius Biotech

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Effettivo)

25 maggio 2026

Completamento primario (Stimato)

25 maggio 2027

Completamento dello studio (Stimato)

22 febbraio 2028

Date di iscrizione allo studio

Primo inviato

27 febbraio 2026

Primo inviato che soddisfa i criteri di controllo qualità

12 marzo 2026

Primo Inserito (Effettivo)

17 marzo 2026

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

24 settembre 2026

Ultimo aggiornamento inviato che soddisfa i criteri QC

21 settembre 2026

Ultimo verificato

1 settembre 2026

Maggiori informazioni

Termini relativi a questo studio

Parole chiave

Termini MeSH pertinenti aggiuntivi

Altri numeri di identificazione dello studio

  • HLX15-SC-NDMM-001

Piano per i dati dei singoli partecipanti (IPD)

Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?

NO

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

Sì

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti

No

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .

Sottoscrivi